Streetbeat News

ICPT

Intercept Pharmaceuticals Inc

Employees

484

Industry

Pharmaceutical Preparation Manufacturing

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Open

19.00

Mkt cap

795M

Volume

3.9M

High

19.01

P/E Ratio

-17.43

52-wk high

21.86

Low

18.98

Div yield

N/A

52-wk low

8.82

The US FDA has announced that Intercept Pharmaceuticals' liver disease drug can cause liver injury in patients without severe scarring, based on postmarket clinical trial data.

Portfolio Pulse from

December 12, 2024 | 3:30 pm

The U.S. FDA has declined full approval for Intercept Pharmaceuticals' liver disease drug, casting uncertainty on its market future.

Portfolio Pulse from

November 12, 2024 | 1:30 pm

Gilead Sciences Inc (GILD) has agreed to acquire CymaBay Therapeutics Inc (CBAY) for $4.3 billion, aiming to enhance its liver disease portfolio with CymaBay's seladelpar for primary biliary cholangitis (PBC). Despite the acquisition not being a major game-changer for Gilead, it's seen as a low-risk move that leverages Gilead's strong commercial capabilities in liver diseases. Seladelpar's potential in addressing pruritus could differentiate it in the PBC market. Baird maintains a Neutral rating on GILD with an $80 price target.

Portfolio Pulse from Vandana Singh

February 13, 2024 | 7:05 pm

Intercept Pharmaceuticals, a subsidiary of Alfasigma S.p.A., has announced new data from a sub-analysis of the Phase 3 POISE trial, which evaluates the impact of obeticholic acid (OCA) on liver biomarkers GGT and ALP in the treatment of primary biliary cholangitis (PBC). The findings suggest that OCA can reduce GGT and ALP levels below thresholds that predict improved outcomes, including survival, in PBC. The data will be presented at the American Association for the Study of Liver Diseases' The Liver Meeting® in Boston.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:02 pm

Alfasigma S.p.A. has announced the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period for its proposed acquisition of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). This satisfies one of the conditions for the tender offer. Other conditions, including a minimum tender of a majority of outstanding Intercept common stock, remain to be satisfied. The offer and withdrawal rights will expire on November 8, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 1:09 pm

The article lists five overbought health care stocks, indicating they may be overvalued: Structure Therapeutics Inc. (GPCR), Olink Holding AB (OLK), Intercept Pharmaceuticals, Inc. (ICPT), NextGen Healthcare, Inc. (NXGN), and HealthStream, Inc. (HSTM). Overbought status is determined by the Relative Strength Index (RSI), with values above 70 indicating overbought conditions. The companies have recent news such as acquisition deals, private placements, and earnings reports.

Portfolio Pulse from Lisa Levin

October 26, 2023 | 12:49 pm

The European Medicines Agency (EMA) has begun a review of Ocaliva, a medicine used to treat primary biliary cholangitis (PBC), following the results of two studies. The studies failed to show that Ocaliva was more effective than a placebo, and side effects, including serious ones, occurred more frequently in patients treated with Ocaliva. The EMA will assess the impact of these findings on the overall benefit-risk balance of Ocaliva and make a recommendation on whether the medicine's marketing authorisation in the EU should be amended.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:57 pm

Benzinga's options activity scanner has identified significant trading activity in the options of ten healthcare stocks. The stocks are ACAD, TEVA, ICPT, IMCR, PTCT, LNTH, OGN, MRK, REGN, and BGNE. The options trades range from bullish call options to bearish put options, with varying expiration dates and strike prices.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:35 pm

Benzinga's options activity scanner has identified significant options activity in the Health Care sector. The stocks involved are BCLI, CVS, ICPT, ZBH, JNJ, EYPT, BBIO, REGN, ALGN, and HZNP. The options activity ranges from bullish to bearish sentiment, with varying expiration dates and strike prices.

Portfolio Pulse from Benzinga Insights

September 28, 2023 | 5:35 pm

B. Riley Securities has downgraded Intercept Pharma from Buy to Neutral, while raising the price target from $15 to $19. The downgrade was announced by analyst Mayank Mamtani.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 4:18 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.